Recombinant polyclonal drug trial for HBV gets FDA green light
Drug Discovery World
AUGUST 7, 2024
The US Food and Drug Administration (FDA) has cleared GigaGen’s application to initiate a Phase I trial of its polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339. In mouse models, GIGA-2339 neutralised and cleared HBV’s viral DNA along with its antigens.
Let's personalize your content